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Inflammation is a response of the immune sys-
tem to physical and/or chemical and/or biological
injury, defined as any process able to cause tissue or
cell damage. Inflammatory processes are cause of a
large number of diseases, such as atherosclerosis,
cancer, asthma, arthritis, and many others (1). 
Theophylline (Th) - 1,3-dimethyl-3,7-dihydro-
purine-2,6-dione has been widely used for the treat-
ment of airway diseases for more than 80 years (2).
More recently, it has been shown to have anti-
inflammatory effects in asthma and chronic obstruc-
tive pulmonary disease (COPD) at lower concentra-
tions. The molecular mechanism of the anti-inflam-
matory effect may be due to inhibition of PDE4 and
histone deacetylase-2 activation, resulting in switch-
ing off activated inflammatory genes (3). Theophyl-
line has a narrow therapeutic index; as a result, toxi-
city can be a significant problem with its chronic use.
This is the reason why new, more efficient and
free of side effects anti-inflammatory medications
are constantly searched for. The modification of a
parent structure of theophylline by introduction of 4-
arylpiperazinyl-alkyl substituent in the 7 position
allowed to receive potent analgesic, antipyretic, and
antiphlogistic agents (4). In this group, the most sig-
nificant activity in several in vivo models (e.g.,
acetic acid writhing test, bradykinin-induced pain
response, carrageenan-induced paw edema) was
observed for compounds possessing 3 ñ 5 carbon
alkyl chain and substituted phenyl ring with elec-
tron-withdrawing chloro/fluoro atom and methyl or
trifluoromethyl group (4).
In the context of a research program that aims
to contribute to the discovery of new anti-inflamma-
tory and analgesic drug candidates, we described the
synthesis and pharmacological evaluation of new 8-
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Abstract: The previous studies in a series of 8-methoxy-1,3-dimethyl-2,6-dioxo-purin-7-yl derivatives revealed
their analgesic properties. We extended the study with these compounds in aim to assess their impact on inflam-
matory process. For this purpose we used: the zymosan-induced peritonitis and the carrageenan-induced edema
model. Furthermore, the antioxidant activity of the investigated compounds by the FRAP assay was determined.
For the most active derivatives from evaluated series their influence on plasma TNF-α level was also tested in
vivo. All investigated purine-2,6-dione derivatives 1-11 decreased neutrophils count and inhibited intensity of
early vascular permeability. Furthermore, all evaluated compounds reduced the volume of edema caused by
subcutaneous injection of carrageenan. Derivatives 1 (with ester moiety), 3 and 4 (with carboxylic group)
showed the highest activity in the zymosan-induced peritonitis. In addition, a significant inhibition of plasma
TNF-α level in rats with endotoxemia was observed following intraperitoneal administration of these com-
pounds. In turn, compounds 6 and 8-11 containing amide moiety showed the greatest anti-inflammatory
(antiedematous) effect in the carrageenan-induced paw edema model. All compounds did not show significant
antioxidant properties. The present studies revealed that the presented purine-2,6-dione derivatives exhibit a
significant anti-inflammatory activity and this effect may result from their ability to lower TNF-α level. 
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alkoxy-1,3-dimethyl-2,6-dioxopurin-7-yl deriva-
tives with ester (1, 2), carboxylic (3, 4) and amide
(5, 6, 8ñ11) terminal groups (5).
We also tested 8-oxo-purine-2,6-dione ana-
logue (7) with an additional acid function in the
form of an enol group (Fig. 1) (5).
The tested compounds 1ñ11 showed analgesic
activity. The strongest analgesic and anti-inflamma-
tory effects were observed for benzylamide (6) or 4-
arylpiperazinamide (8ñ11) derivatives, which were
more active than acetylic acid used as a reference
drug (up to 23- and 36-fold increase in activity in
writhing and formalin test, respectively). Several
compounds more active than theophylline inhibited
the phosphodiesterase activity in rat liver
homogenates (5).
In the present paper, the results of further phar-
macological studies in a group of 8-alkoxy-1,3-
dimethyl-2,6-dioxo-purin-7-yl derivatives (1ñ11)
are described. They concern the evaluation of anti-
inflammatory activity of these compounds in the
zymosan-induced peritonitis model and the car-
rageenan-induced hind paw edema model in mice.
We also assessed their activity in in vitro FRAP
assay estimating the total ferric reducing antioxidant
power. Finally, the effect of the most active theo-
phylline derivatives on plasma TNF-α level in rat
model of endotoxemia was investigated.
EXPERIMENTAL
Chemistry
The multistep syntheses of the investigated
compounds 1-11 (Fig. 1) were previously reported
(5). Firstly, in a reaction of 8-bromo-1,3-dimethyl-
1H-purine-2,6(3H,7H)-dione -7-alkylcarboxylates
with sodium methanolate in a methanol medium
the methyl 2-(8-methoxy-1,3-dimethyl-2,6-dioxo-
2,3-dihydro-1H-purin-7(6H)-yl)acetate (1) and
this higher butyrate homolog (2) were obtained.
Corresponding acids 3 and 4 were prepared by
alkaline hydrolysis of 1 and 2, respectively, using
acetone-water (1 : 2, v/v) solution of KOH and
then by acidification with HCl. The methyl 2-(1,3-
dimethyl-2,6,8-trioxo-2,3,8,9-tetrahydro-1H-
purin-7(6H)-yl)acetate (7) was synthesized by
acidic hydrolysis of 1 following by estrification
with methanol. Benzylamides (5, 6) and arylpiper-
azinamides (8ñ11) were prepared in a reaction of 3
and 4 with respective amine (benzylamine or 1-
arylpiperazine derivatives), using 1,1í-car-
bonylimidazole (CDI) as carbonyl group activat-
ing agent in DMF medium (5). The chemical
structure of compounds 1-11 were confirmed by
spectral data (1H-NMR, LC/MS) and elemental
analyses and the purity were establish using
LC/MS method. All the investigated compounds
have purity over 98% (5).
Pharmacology
Animals
Experiments were carried out on male Wistar
rats weighing 180-220 g and male albino Swiss mice
(18ñ26 g). The animals were housed in constant
temperature facilities exposed to 12 : 12 light-dark
cycle and maintained on a standard pellet diet and
tap water given ad libitum. Control and experimen-
tal groups consisted of 6-8 animals each. The inves-
tigated compounds were administered intraperi-
toneally (i.p.) in a form of suspension in 0.5%
methylcellulose. Control animals received the
equivalent volume of solvent.
Male Wistar rats weighing 200-250 g bred in-
house from progenitors obtained from Charles River
Laboratories (Sulzfed, Germany) were used to
assess the influence of theophylline derivatives on
plasma TNF-α levels in a model of endotoxemia.
Animals were fasted overnight prior to drug admin-
istration but had free access to water.
All procedures were conducted according to
guidelines of ICLAS (International Council on
Laboratory Animals Science) and were approved by
The Local Ethics Committee of the Jagiellonian
University in KrakÛw (agreement nr 47/2014). 
Figure 1. Chemical structures of the compounds 1ñ11 (5)
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Drugs and chemicals
LPS (Escherichia coli 055:B5), methylcellu-
lose, carrageenan, zymosan A, Evans blue, ketopro-
fen, indomethacin, acetate buffer, FeCl3∑6H2O,
TPTZ (2,4,6-tripyridyl-s-triazine), theophylline,
ascorbic acid were purchased from Sigma-Aldrich
(St. Louis, MO, USA). 
Carrageenan-induced edema model
Wistar rats weighing 180-220 g were used in
the ìhind paw edemaî test. Animals were divided
into four groups, one of them being the control. In
order to produce inflammation, 0.1 mL of 1% car-
rageenan solution in water was injected into the hind
paw subplantar tissue of rats, according to the mod-
ified method of C.A. Winter (6) and P. Lence (7).
The development of paw edema was measured with
a plethysmometer (Plethysmometer 7140, Ugo
Basile). Prior to the administration of test sub-
stances, paw diameters were measured by dividers
and recorded. The investigated compounds were
administered at doses of 5, 10, 25, 50, 100 mg/kg,
i.p. (as a suspension in methylcellulose), prior to
carrageenan injection. Methylcellulose was admin-
istered by the same route, to the control group
(methylcellulose had no effect on edema, data not
shown). After these administrations, paw diameters
were measured at 1, 2 and 3 h. The percent, of
edema and edema inhibition were calculated accord-
ing to the equations given below.
Edema % = (Ní ◊ 100) / N
Edema inhibition % = (N ñ Ní ◊ 100) / N
where N = paw diameters measured 1, 2 and 3 h
after injection of carrageenan to the control group
paw diameters at the beginning; Ní = paw diameters
measured 1, 2, and 3 h after injection of carrageenan
to the test groups paw diameters at the beginning.
Zymosan-induced peritonitis 
Peritoneal inflammation was induced as
described previously (8). Zymosan A was freshly
prepared (2 mg/mL) in sterile 0.9% NaCl. Thirty
min after subcutaneous (s.c.) injection of the inves-
tigated compounds into the loose skin over the
flank, zymosan A was injected i.p. in a volume of
0.25 mL. Four hours later, the animals were killed.
The peritoneal cavity was lavaged with 1.5 mL of
saline and after 30 s of gentle manual massage the
exudates were retrieved. Cells were counted using
an automatic cell counter (Countess, Invitrogen) fol-
lowing staining with Turkís solution. The investi-
gated compounds suspended in 0.5% methylcellu-
lose were injected s.c. at the dose of 50 mg/kg b.w.
and pitched in an ultrasonic cleaner. The control
group was given s.c. 0.5% methylcellulose 30 min
prior to zymosan. 
Vascular permeability 
The compounds suspended in 0.5% methylcel-
lulose were injected s.c. at the dose of 50 mg/kg b.w.
Then, after 30 min, Evans blue was suspended in
saline (10 mg/mL) and injected intravenously (i.v.)
into the caudal vein (0.2 mL/mouse), which was
immediately followed by i.p. injection of zymosan
A. Thirty minutes later the animals were killed and
their peritoneal cavities were lavaged with 1.5 mL of
saline as described above. The lavage fluid was cen-
trifuged and the absorbance of the supernatant was
measured at 620 nm as described previously (9). The
investigated compounds suspended in 0.5% methyl-
cellulose were injected s.c. 30 min before Evans
blue and zymosan. The control group was given s.c.
0.5% methylcellulose 30 min prior to zymosan.
Indomethacin in a dose of 50 mg/kg b.w. was used
as a reference compound.
Determination of the antioxidant activity by the
FRAP assay
The FRAP assay was conducted according to
Benzie and Strain (10) with some modifications.
The stock solutions included 300 mM acetate buffer
(3.1 g C2H3NaO2 ◊ 3H2O and 16 mL C2H4O2), pH
3.6, 10 mM TPTZ (2,4,6-tripyridyl-s-triazine) solu-
tion in 40 mM HCl, and 20 mM FeCl3 ◊ 6H2O solu-
tion was prepared by mixing 10 parts of acetate
buffer, 1 part of TPTZ solution, and 1 part of FeCl3
◊ 6H2O solution. Three hundred µL of the FRAP
solution was mixed with 10 µL of the test compound
solution and incubated at room temperature for 10
min in the dark. Readings of the colored product
(ferrous tripyridyltriazine complex) were then taken
at 593 nm against ethanol. The results for the test
compounds are expressed as an increase in
absorbance of the test sample compared to a sample
containing the solvent. 
In the FRAP assay the antioxidant potential of
the sample was determined from a standard curve
plotted using FeSO4 ◊ 7H2O in a concentration range
between 37.5 and 1200 µM.
LPS-induced endotoxemia 
Rats were cannulated in the jugular vein under
ketamine/xylazine anesthesia three days before the
experiment. All catheters were filled with
heparinized saline and exteriorized via an incision on
the back of the neck. In order to induce endotoxemia,
an intravenous dose of 1 mg/kg lipopolysaccharide
(LPS) from E. coli serotype 055:B5 was adminis-
764 MA£GORZATA ZYGMUNT et al.
tered prior to compound administration. Compounds
1, 3, 4, 6, 7, 9 and theophylline (Th) as a reference
drug suspended in 0.5% methylcellulose were given
to rats (n = 4-5) at a dose of 50 mg/kg i.p. simultane-
ously with LPS. Control animals received LPS and a
respective volume of vehicle by the same routes of
administration as the treatment groups. Blood sam-
ples (300 µL) were collected into heparinized tubes
at 0, 15, 30 min and 1, 1.5, 2, 3, and 4 h after LPS and
compound administration. The animals were injected
with an equal volume of 0.9% saline through the tub-
ings after each blood collection. Blood was cen-
trifuged at 4OC for 20 min (1500 ◊ g). Plasma was
stored at ñ80OC until assayed. 
Determination of plasma TNF-α levels 
Tumor necrosis factor α (TNF-α) concentra-
tions in rat plasma were measured using ELISA
(R&D Systems, Minneapolis, MN, USA) according
to the manufacturerís instructions. Limit of quantifi-
cation was 13 pg/mL.
Statistical analysis
The data are expressed as the mean ± SEM
(standard error of the mean). To compare the results
between two different groups of animals (the inves-
tigated compound group vs. the control group)
Studentís t-test was used. The difference of means
was statistically significant if p < 0.05. The results
of carrageenan-induced paw edema experiments are
expressed as a percentage of change from control
(pre-drug) values. The data were evaluated by one-
way analysis of variance (ANOVA) followed by
Duncanís test. A probability value < 0.05 was con-
sidered statistically significant.
Table 1. Antiinflammatory effect of the compounds in the carrageenan-induced paw edema test.
Dose Change in edema volume [mL]
Compound mg/kg 1 h 2 h 3 h
Control - 0.9 ± 0.01 1.35 ± 0.01 1.52 ± 0.09  
1 100 0.5 ± 0.09 0.25 ± 0.08** 0.030 ± 0.004***
50 0.65 ± 0.07 0.35 ± 0.05* 0.25 ± 0.03**  
2 100 0.25 ± 0.03* 0.23 ± 0.04** 0.18 ± 0.02**
50 0.73 ± 0.08 0.35 ± 0.06* 0.25 ± 0.08*  
3 100 0.6 ± 0.07 0.08 ± 0.006*** 0.020 ± 0.001***
50 0.75 ± 0.09 0.3 ± 0.07* 0.18 ± 0.02**  
4 100 0.6 ± 0.07 0.38 ± 0.09* 0.050 ± 0.004***
50 0.6 ± 0.04 0.325 ± 0.02* 0.25 ± 0.03**  
5 100 0.5 ± 0.03 0.080 ± 0.007*** 0.020 ± 0.001***
50 0.6 ± 0.08 0.375 ± 0.09* 0.28 ± 0.02**
Control - 0.9 ± 0.13 1.04 ± 0.1 1.22 ± 0.09  
6 25 0.075 ± 0.005*** 0.175 ± 0.01*** 0.1 ± 0.07***
10 0.475 ± 0.09* 0.175 ± 0.01*** 0.1 ± 0.07***  
7 100 0.52 ± 0.08 0.21 ± 0.05** 0.030 ± 0.005***
50 0.61 ± 0.04 0.37 ± 0.05* 0.22 ± 0.03**  
8 25 0.1 ± 0.02*** 0.01 ± 0.002*** 0.075 ± 0.005***
10 0.175 ± 0.03** 0.125 ± 0.009*** 0.15 ± 0.009***  
9 25 0.2 ± 0.04*** 0.075 ± 0.008*** 0.125 ± 0.02***
10 0.225 ± 0.01** 0.325 ± 0.02** 0.15 ± 0.009***  
10 25 0.175 ± 0.03** 0.125 ± 0.04*** 0.1 ± 0.006***
10 0.65 ± 0.1 0.35 ± 0.07** 0.15 ± 0.03***  
11 25 0.225 ± 0.05** 0.175 ± 0.01*** 0.075 ± 0.003***
10 0.2 ± 0.06** 0.125 ± 0.009*** 0.15 ± 0.005*** 
Data are presented as the means ± SEM of 6ñ8 animals per group. The results were analyzed by one-way analysis of variance (ANOVA)
* p < 0.05,** p < 0.01,*** p < 0.001 vs. control value at respective time points.
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Comparisons between maximum TNF-α levels
and the area under effect-time curve (AUEC) were per-
formed using a one-way ANOVA with post-hoc Tukey
HSD test (Statistica v. 10, StatSoft, USA). AUEC was
calculated using Phoenix WinNonlin v. 6.3 (Pharsight
Corporation, Mountain View, CA, USA). 
RESULTS 
Anti-inflammatory (antiedematous) effect in the
carrageenan-induced edema model
All new 8-alkoxy-1,3-dimethyl-2,6-dioxo-
purin-7-yl derivatives were first administered at a
dose of 10 mg/kg. In the case of the compounds that
were not active at this dose, in the next step, they
were administered at higher doses, while others at a
lower dose. Therefore, the compounds 1ñ5 and 7
were administered at doses from 100 to 10 mg/kg
body weight, whereas compounds 6 and 8ñ11 at
doses from 25 to 5 mg/kg b.w. Ketoprofen was used
as a reference compound. Ketoprofen administered
i.p. at a dose of 100 mg/kg b.w. inhibited edema for-
mation by 80.0%, 75.7%, and 80.6%, in three con-
secutive hours of the experiment, respectively.
When administered i.p. at a dose of 20 mg/kg b.w. it
inhibited edema formation by 20, 54 and 67% in
three consecutive hours of the experiment, respec-
tively. 
All test compounds decreased the volume of
edema induced by s.c. carrageenan injection into the
hind paw of rats (Table 1). 
A statistically significant antiedematous effect
was observed after the administration of compound
1 at two doses. The doses of 100 mg/kg b.w. and 50
mg/kg b.w. reduced edema by 81.4-98.0% and 74.0-
83.5% in the 2nd and 3rd hour of observation, respec-
tively (Table 1). Compound 2 had a similar effect.
Its administration at a dose of 100 mg/kg b.w. low-
ered edema by 72.2-88.1% throughout the whole
experimental period. On the other hand, administra-
tion of this compound at a dose of 50 mg/kg b.w.
decreased edema in the 2nd and 3rd hour of the exper-
iment by 74.0 and 83.5%, respectively. Compound 3
also demonstrated a statistically significant effect in
this experimental model. When administered i.p. at
a dose of 100 mg/kg b.w., it inhibited edema forma-
tion by 94.0 and 98.6% in the 2nd and 3rd hour of the
experiment, respectively, while its dose of 50 mg/kg
b.w. reduced edema by 77.7 and 88.1%. Similarly,
compound 4 when administered i.p. at a dose of 100
mg/kg b.w. inhibited edema development by 71.8
and 96.7% in the 2nd and 3rd hour of the experiment,
respectively, and the differences reached statistical
significance. Its administration at a dose of 50
mg/kg b.w. lowered edema by 75.9 and 83.5%.
Anti-inflammatory effect of the lowest dose of 10
mg/kg b.w. was diminished. 
Administration of compound 5 at a dose of 100
mg/kg b.w. i.p. caused edema inhibition by 94.0 and
98.6% in the 2nd and 3rd hour of the experiment,
respectively, while given at a dose of 50 mg/kg b.w.
lowered edema by 72.2 and 81.5% (Table 1). 
Compound 6 also exhibited a statistically sig-
nificant effect in this experimental model. When
administered i.p. at a dose of 25 mg/kg b.w., it inhib-
ited edema formation by 91.6, 83.2, and 91.8% in
the 1st, 2nd and 3rd hour of the experiment, respective-
ly. Its dose of 10 mg/kg b.w. reduced edema by 47.2,
83.2, and 91.8%. A statistically significant antiede-
matous effect was observed after the administration
of compound 7 at two doses. Doses of 100 mg/kg
b.w. and 50 mg/kg b.w. reduced edema by 79.8-
64.4% and 97.5-81.9% in the 2nd and 3rd hour of
observation, respectively. Compound 8 when
administered at doses 25 mg/kg b.w. and 10 mg/kg
b.w. significantly lowered edema throughout the
whole observation period by 88.8-93.8% and 80.5-
87.7%, respectively. 
Compound 9 showed anti-inflammatory effect
in a dose range from 5 mg/kg b.w. to 25 mg.kg b.w.
but only two highest doses significantly reduced
edema formation by 68.7-92.7% (Table 1). The
theophylline derivative 10 at a dose of 25 mg/kg
b.w. produced a strong anti-inflammatory effect
inhibiting edema of the mouse hind paw by 80.5, 88
and 91.8% in the 1st, 2nd and 3rd hour after car-
rageenan injection, respectively. When the dose
was lowered, the activity of this compound slightly
decreased. Compound 11 administered at doses of
25 mg/kg b.w. and 10 mg/kg b.w. demonstrated a
significant anti-inflammatory effect. This effect
increased with elapsing time of the experiment
reaching the maximum in the 3rd hour. Dose lower-
ing caused extinction of the anti-inflammatory
activity.
The effects of the compounds on vascular perme-
ability during zymosan-induced peritonitis
The effect of the investigated compounds on
vascular permeability was tested at the dose of 50
mg/kg b.w. Indomethacin at the dose of 50 mg/kg
b.w. was used as a reference compound. The inten-
sity of early vascular permeability was significantly
inhibited in the groups receiving compounds 1, 3
and 4 compared to the control group (Table 2).
These compounds decreased the vascular permeabil-
ity by 94.3-81.2%. The reducing effect on the vas-
cular permeability of these compounds was greater
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than that of indomethacin. The early vascular per-
meability was significantly inhibited also in the
groups receiving compounds 5-11 compared to the
control group (Table 2). These compounds decre-
ased the vascular permeability by 77.3 to 61.1%. In
turn, compound 2 influenced vascular permeability
during zymosan-induced peritonitis, but the effect
was not statistically significant.
The effects of the compounds on infiltration of
neutrophils during zymosan-induced peritonitis
The effect of the investigated compounds on
infiltration of neutrophils was tested at the dose of
50 mg/kg b.w. The early infiltration of neutrophils
measured at 4 hours following zymosan injection
was significantly stronger than that of indomethacin
and was inhibited in the group receiving compound





Control - 2.230 ± 0.180 -
1 50 0.138 ± 0.050 93.8***
2 50 1.400 ± 0.190 37.2
3 50 0.126 ± 0.070 94.3***
4 50 0.418 ± 0.040 81.2**
5 50 0.739 ± 0.021 66.8*
6 50 0.728 ± 0.028 67.3*
7 50 0.700 ± 0.030 68.6*
8 50 0.825 ± 0.039 63.0*
9 50 0.588 ± 0.060 77.3**
10 50 0.798 ± 0.046 64.2*
11 50 0.867 ± 0.063 61.1*
Indomethacin 50 0.456 ± 0.120 79.5**  
Data are presented as the means ± SEM of 6ñ8 mice per group. The results were analyzed by Student t-test, 
* p < 0.05,** p < 0.01,*** p < 0.001 vs. control.
Table 3. Percent inhibition of neutrophil infiltration in zymosan-induced peritonitis in mice.
Compound
Dose Count of Inhibition
[mg/kg]  neutrophils %
Control - 6.4 ◊ 106 ± 0.76 -
1 50 8.3 ◊ 105  ± 0.92 87.0**
2 50 4.4 ◊ 106  ± 1.36 31.2
3 50 2.1 ◊ 105  ± 0.18 96.7***
4 50 8.4 ◊ 105  ± 0.28 86.8**
5 50 2.1 ◊ 106  ± 0.16 67.1*
6 50 1.9 ◊ 106  ± 0.26 70.3*
7 50 2.4 ◊ 106  ± 0.15 62.5*
8 50 2.9 ◊ 106  ± 0.62 54.6*
9 50 1.7 ◊ 106  ± 0.85 73.4*
10 50 2.6 ◊ 106  ± 0.74 59.3*
11 50 1.9 ◊ 106  ± 0.62 70.3*
Indomethacin 50 9.8 ◊ 105  ± 0.29 84.6**  
Data are presented as the means ± SEM of 6-8 mice per group. The results were analyzed by Student t-test, 
* p < 0.05,** p < 0.01,*** p < 0.001 vs. control.
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1 (decrease by 87.0%) and in the group treated with
3 (decrease by 96.7%), and 4 (decrease by 86.8%).
The early infiltration of neutrophils was signif-
icantly inhibited also in the groups receiving com-
pounds 5-11 compared to the control group. These
compounds decreased the count of neutrophils by
73.4 to 59.3% (Table 3). Compound 2 influenced
infiltration of neutrophils during zymosan-induced
peritonitis, but the effect was statistically non-sig-
nificant.
Antioxidant activity measured by the FRAP
assay
Investigation of the effect of the test com-
pounds on the total antioxidant power revealed that
9 of them: 1, 2, 4 and 6-11 at a concentration of 10-5
M increased the total ferric reducing antioxidant
ability by 0.29ñ3.7% of the maximum value
obtained for ascorbic acid at the same concentration.
The remaining compounds did not show an antioxi-
dant effect in this test. 
Inhibition of TNF-α production in vivo
Administration of compounds 1, 3, 4, 6, 7, and
9 to rats with LPS-induced endotoxemia caused a
significant inhibition of TNF-α production in plas-
ma (Fig. 2). The most pronounced effect was
observed in the presence of compounds 3 and 1. The
maximum concentration of TNF-α achieved at 1.5 h
following LPS administration decreased significant-
ly from 20157 pg/mL (LPS + vehicle) to 2579 and
3269 pg/mL, respectively (Fig. 3). At the same time,
compounds 4 and 9 decreased the maximum con-
centration of TNF-α by 75.9 and 71.8%, respective-
ly, and these differences were also statistically sig-
nificant. The weakest inhibitory effect exhibited
compounds 6 and 7. For these compounds TNF-α
cytokine concentrations at 1.5 h were more than 3
times higher when compared with the strongest
inhibitor of TNF-α that is compound 3 (a decrease by
57.6 and 55.7% compared to the control group, i.e.,
LPS + vehicle). In addition, these concentrations
were 1.5 times higher than that observed following
Figure 2. TNF-α concentration as a function of time following intraperitoneal administration of selected xanthine derivatives (50 mg/kg)
to rats with endotoxemia (n = 4ñ5), (left panel: 0ñ25000 pg/mL, right panel: 0ñ10000 pg/mL)
Figure 3. Maximum TNF-α concentration (left panel) and AUEC (right panel) observed following administration of LPS (1 mg/kg, i.v.)
simultaneously with vehicle only or studied compounds given i.p. at a dose of 50 mg/kg to rats (n = 4ñ5). * < 0.05 vs. LPS + vehicle, (one-
way ANOVA with post-hoc Tukey test)
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Th administration (5665 pg/mL) used as a reference
compound in this study. Similar differences were
observed between the areas under effect curve
(AUEC) calculated based on the individual TNF-α -
time profiles in the vehicle group and all study
groups (Fig. 3). 
DISCUSSION AND CONCLUSION
The aim of the study was to evaluate of anti-
inflammatory activity of new methylxanthine deriv-
atives. For this purpose we used zymosan-induced
peritonitis and the carrageenan-induced hind paw
edema models in animals (11). The carrageenan test
is used to evaluate the anti-inflammatory effect;
injection of this compound into the hind paw of an
animal induces a long-lasting edema (12, 13). 
The carrageenan-induced paw edema model
demonstrated that compounds 6 and 8-11 containing
amide substituent showed the greatest anti-inflam-
matory (antiedematous) effect. The effect of all
these compounds was comparable and increased
with time elapsing from the beginning of the exper-
iment reaching the maximum in the 3rd hour. The
effect was dose-dependent. The above compounds
produced the highest statistically significant effect at
the dose of 25 mg/kg b.w. All these methylxanthine
derivatives revealed a stronger action compared
with ketoprofen. The administration of a lower dose
of 10 mg/kg b.w. only slightly diminished anti-
inflammatory activity. 
The remaining compounds showed also anti-
inflammatory activity but at higher doses as they
were administered at 100-10 mg/kg b.w. in this test.
A statistically significant effect was observed
(except for compound 2) only in the 2nd and 3rd hour
of the experiment. The administration of a lower
dose of 50 mg/kg b.w. induced only a minute lower-
ing of anti-inflammatory activity. 
Murine zymosan-induced peritonitis was
described as a suitable model of acute inflammation,
characterized by vascular changes and production of
inflammatory mediators leading to leukocyte accu-
mulation in the inflammatory focus (14, 15). Two
major events are critical for development of
zymosan-induced peritonitis, namely the early
increase in vascular permeability (< 1 h) and the
infiltration of neutrophils into the peritoneum that
follows after some hours (9). The mechanisms oper-
ating during the above stages have been investigat-
ed and these studies revealed that early vascular per-
meability depends mostly on cysteinyl-leukotrienes
released by resident peritoneal macrophages and, to
lesser extent, on mast cell histamine and
prostaglandins (PGE2, prostacyclin) of multiple cel-
lular origins (9).
This study focused on two major events lead-
ing to the development of inflammation, i.e., the
early increase in vascular permeability and neu-
trophil infiltration into peritoneum. The results indi-
cated that the compounds under investigation
demonstrated anti-inflammatory activity in both
tests. In the study of cellular infiltration they signif-
icantly limited the migration of leukocytes to site of
inflammation, which was the peritoneum. 
Compounds 1 (with ester terminal moiety) as
well as 3 and 4 (containing carboxylic group)
showed the strongest anti-inflammatory activity in
the zymosan-induced peritonitis.
Compounds 3 and 4 with terminal carboxylic
moiety significantly reduced the vascular permeabil-
ity by 94.3 and 81.2% and inhibited infiltration of
neutrophils by 96.7 and 86.8%, respectively, com-
pared to the control group. In turn, 8-alkoxy-1,3-
dimethyl-2,6-dioxopurin-7-yl derivative with ester
terminal group, i.e., compound 1 reduced the vascu-
lar permeability by 93.8% and inhibited infiltration
of neutrophils by 87.0%, while 8-oxo-purine-2,6-
dione analogue (compound 7) reduced the vascular
permeability by 68.6% and inhibited infiltration of
neutrophils by 62.5%. The statistical analysis
showed that compounds 6 and 8-11 (containing
amide and benzylamide) significantly reduced the
vascular permeability by 61.1-77.3% compared to
the control group. The obtained data also demon-
strated that administration of these compounds at the
same dose (50 mg/kg b.w.) significantly inhibited
infiltration of neutrophils by 54.6-73.4%.
Summing up, all compounds 1-11 showed sta-
tistically significant anti-inflammatory activity in
both tests: the carrageenan-induced edema test and
the zymosan-induced peritonitis (except for com-
pound 2). They significantly reduced the early vas-
cular permeability, inhibited infiltration of neu-
trophils and tempered paw edema formation. In the
carrageenan-induced paw edema model, compounds
6 and 8-11 showed the greatest anti-inflammatory
(antiedematous) effect. In the case of the zymosan-
induced peritonitis, compounds 3 and 1 followed by
4 and 9 revealed the greatest anti-inflammatory
activity. 
The mechanism of tissue damage due to
inflammatory processes has been partly linked to the
release of reactive oxygen species (ROS) from acti-
vated neutrophils and macrophages. Excessive ROS
production leads to tissue damage by degradation of
macromolecules and peroxidation of membrane
lipids. On the other hand, reactive oxygen species
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support and spread inflammation by the stimulation
of cytokine production (IL-1, TNF-α, INF-γ) which
increase further neutrophil and macrophage influx
(16). Thus, free radicals are indispensable mediators
of inducing and maintaining inflammation while
their neutralization by antioxidants and free radical
scavengers can limit its severity (17).
In order to elucidate anti-inflammatory activity
of theophylline derivatives, we determined the total
ferric reducing antioxidant power (FRAP). The
pharmacological studies demonstrated that the test
compounds were practically almost completely
devoid of antioxidant activity. Therefore, their anti-
inflammatory activity does not result from the influ-
ence on the total antioxidant potential.
Due to the important role of TNF-α in inflam-
mation, further attempts to clarify the mechanism of
action of the most active test compounds involved
determination of TNF-α levels after their adminis-
tration to rats with LPS-induced endotoxemia.
TNF-α is one of the major proinflammatory
cytokines that stimulates the release of other media-
tors of inflammation, thereby inciting further
inflammatory responses (18). The TNF-α expres-
sion is mainly under the regulatory control of
nuclear factor-κB (NF-κB).
LPS-induced models of sepsis and septic-
shock are commonly used to evaluate efficacy of
anti-inflammatory drugs (19). In vitro methods
employing LPS-stimulated whole blood or murine
macrophages, although less cost- and time-consum-
ing, may provide results not entirely reflecting in
vivo drug activity. It has been shown that IC50 values
assessed in vitro were up to 10 times higher than
those estimated in vivo (20). Thus, it seems that inhi-
bition of TNF-α production following LPS adminis-
tration to animals may be more appropriate to study
the true efficacy of new compounds than in vitro
methods.
The results of the in vivo experiment on a series
of the investigated purine-2,6-dione derivatives in
rats with endotoxemia indicate that all compounds
studied significantly inhibited TNF-α production in
rat plasma (Figs. 3 and 4). The results of the in vivo
study indicate that among compounds studied 1 and
3 and also 4 and 9 are the strongest inhibitors of
TNF-α production in rat plasma. For these com-
pounds TNF-α concentrations were lower than that
observed for theophylline used in this study as a ref-
erence compound. In addition, these compounds
most strongly inhibited infiltration of neutrophils in
the zymosan-induced peritonitis. Based on the
results of preliminary study performed in our labo-
ratory, compounds 1 and 3 are the weakest phos-
phodiesterase (PDE) inhibitors as assessed using rat
liver homogenates (5). The strongest inhibition of
PDE in the liver homogenates revealed compounds
6 and 7 (5). For these compounds TNF-α concentra-
tions at 1.5 h were higher than that observed for
theophylline. 
This discrepancy between TNF-α and PDE-
inhibition by studied compounds may be explained
by differences in distribution pattern and relative
abundance of PDEs in plasma and liver. For exam-
ple, in CD4+ and CD8+ T-lymphocyte homogenates,
substantial PDE 4 and PDE 3 and only low PDE 1, 2
and 5 activities were observed (21). Recently, it has
been shown that PDE 4A, PDE 4B, PDE 4D and
PDE 7A mRNA are present in similar quantities in
both CD4+ and CD8+ lymphocytes (22). Monocytes
exclusively contain PDE 4 but their in vitro matura-
tion leads to a PDE isoenzyme profile similar to that
of alveolar macrophages (23). In turn, in the liver,
PDE 2-4, 8, 9, and PDE 11 show relatively high
expression, whereas PDE 7 is not detected.
Thus, TNF-α inhibition by new methylxantine
derivatives observed in the study seem to be related
to the increased levels of cAMP (an inhibitor of the
NF-κB pathway) that is assumed to be the most
important mechanism of action of most xanthines
with anti-inflammatory activity (24, 25) or to a
direct inhibition of NF-κB activation. The mecha-
nism of compounds in reducing inflammation is
thought to be due to inhibition of TNF-α, a cytokine
that has been shown to increase leukocyte adhesion
and to disrupt intercellular junctions of postcapillary
venular endothelium, leading to plasma extravasa-
tion. In the carrageenan-induced paw edema model,
derivatives of theophylline reduced the edema
response and in addition, inhibited infiltration of
neutrophils in the zymosan-induced peritonitis.
Probably the test compounds by reducing TNF-α act
on endothelial cells inhibiting the expression of
adhesion molecules and chemokines necessary for
the accumulation of white blood cells at the site of
inflammation.
In the next stage of research on these com-
pounds it is planned to test whether they have the
ability to inhibit histone deacetylase, cyclooxyge-
nase and Transient Receptor Potential (TRP)
ankyrin 1 (TRPA1). Review of world literature pro-
vides data confirming that the anti-inflammatory
effect of some drugs (including theophylline) results
from the influence on histone deacetylase and ion
channels TRPA1 (26, 27).
In summary, the study indicates that the 8-
alkoxy-1,3-dimethyl-2,6-dioxo-purin-7-yl deriva-
tives (1-11) are a new class of compounds with anti-
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inflammatory activities. The carrageenan-induced
paw edema model demonstrated that compounds 6
and 8-11 containing amide substituent showed the
greatest anti-inflammatory (antiedematous) effect.
The compounds with carboxylic (3, 4) and ester
moiety (1) showed the highest anti-inflammatory
activity in the zymosan-induced peritonitis. They
significantly decreased neutrophils count and inhib-
ited intensity of early vascular permeability. In addi-
tion, especially compound 3 and also compound 1
significantly inhibited of TNF-α production in plas-
ma of rats with endotoxemia and this effect was
stronger than that of theophylline. Compounds did
not show significant antioxidant properties.
Therefore, their beneficial effects observed in the
models of inflammation used in this study are not
related to the influence on the total antioxidant
potential. The results obtained indicate that the
mechanism of anti-inflammatory activity of com-
pounds is probably related to the inhibition of TNF-
α release.
REFERENCES
1. Ca≥kosiÒski I., DobrzyÒski M., Ca≥kosiÒska M.,
Seweryn E., Bronowicka-Szyde≥ko A. et al.:
Postepy Hig. Med. Dosw. 63, 395 (2009).
2. Talik P., Krzek J., Ekiert R.J.: Sep. Purif. Rev.
41, 1 (2012).
3. Barnes P.J.: Am. J. Respir. Crit. Care Med. 188,
901 (2013).
4. Kaneko T.: US 4,599,337 (1985). 
5. Zygmunt M., Ch≥oÒ-Rzepa G., Sapa J.,
Paw≥owski P.: Pharmacol. Rep. 67, 9 (2015).
6. Winter C.A., Risley E.A., Nuss G.W.: Proc.
Soc. Exp. Biol. Med. 111, 544 (1962).
7. Lence P.: Arch. Int. Pharmacodyn. Ther. 136,
237 (1962).
8. Kolaczkowska E., Grzybek W., van Rooijen N.,
Piccard H., Plytycz B. et al.: J. Leukoc. Biol. 85,
374 (2009).
9. Kolaczkowska E., Barteczko M., Plytycz B.,
Arnold B.: Inflamm. Res. 57, 272 (2008).
10. Benzie I. F., Strain J.J.: Anal. Biochem. 239, 70
(1996).
11. Abdel-Salam O.M., Baiuomy A.R., El-
Shenawy S.M., Arbid M.S.: Pharmacol. Res. 4,
47 (2003).
12. de Barros B.S., da Silva J.P., de Souza Ferro
J.N., Agra I.K., de Almeida Brito F. et al.: J.
Nat. Med. 65, 526 (2011).
13. Ramos-Zepeda G., Herrero J.F.: Neurosci. Lett.
384, 177 (2005).
14. Santos E.N., Lima J.C., Noldin V.F., Cechinel-
Filho V., Rao V.S. et al.: An. Acad. Bras. Cienc.
83, 557 (2011).
15. Zygmunt M., Dudek M., Bilska-Wilkosz A.,
Bednarski M., Mogilski S. et al.: Acta Pol.
Pharm. Drug Res. 70, 899 (2013).
16. Lee H.N., Kundu J.K., Cha Y.N., Surh Y.J.: J.
Cell. Sci. 126, 4037 (2013).
17. Conforti F., Sosa S., Marrelli M., Menichini F.,
Statti G.A. et al.: J. Ethnopharmacol. 116, 144
(2008).
18. Borges V.M., Vandivier R.W., McPhillips
K.A., Kench J.A., Morimoto K. et al.: Am. J.
Physiol. Lung. Cell. Mol. Physiol. 297, L586
(2009).
19. Buras J.A., Holzmann B., Sitkovsky M.: Nat.
Rev. Drug. Discov. 4, 854 (2005).
20. Magee M.H., Blum R.A., Lates C.D., Jusko
W.J.: Br. J. Clin. Pharmacol. 53, 474 (2002).
21. Tenor H., Staniciu L., Schudt C., Hatzelmann
A., Wendel A. et al.: Clin. Exp. Allergy 25, 616
(1995).
22. Jones N.A., Leport M., Holand T., Vos T.,
Morgan M. et al.: Pulm. Pharmacol. Ther. 20,
60 (2007).
23. Tenor H., Hatzelmann A., Kupferschmidt R.,
Stanciu L., Djukanovic R. et al.: Clin. Exp.
Allergy 25, 625 (1995).
24. Sinha B., Semmler J., Eisenhut T., Eigler A.,
Endres S.: Eur. J. Immunol. 25, 147 (1995).
25. Semmler J., Gebert U., Eisenhut T., Moeller J.,
Schonharting M.M. et al.: Immunology 78, 520
(1993).
26. Chen H.Y., Li L., Fu Z.J.: Pharmazie 69, 55
(2014).
27. Zygmunt M., Zmudzki P., Chlon-Rzepa G.,
Sapa J., Pawlowski M.: Lett. Drug Des. Discov.
11, 1204 (2014).
Received: 25. 03. 2015
